Real-world Lenire outcomes: US clinic chart review
Record details
- Authors: Kasper CA, May JM, Crossland NE, Lim HH
- Journal / source: American Journal of Audiology (2026)
- Design: Retrospective single-site chart review
- Sample: 140 fitted (66 of 104 'bothered' patients analyzed at 12 weeks)
- Primary endpoint: THI change
- Randomized: No · Sham/placebo-controlled: No · Independent of the manufacturer: No
What this research found
Among the 66 bothered-tinnitus patients (THI≥38) with 12-week data, 81.8% (95% CI 70.9–89.3) achieved ≥7-point THI improvement; mean −23.8 points. Non-bothered patients showed essentially no change.
Uncontrolled real-world data with substantial follow-up attrition (66/104) and counseling co-intervention; consistent with trials but cannot separate treatment from placebo/natural course.
Limitations and conflicts of interest
Retrospective, uncontrolled, manufacturer-linked, 37% attrition in the analyzed group.
Funding / conflicts: Senior author Hubert Lim is Neuromod's CSO; Neuromod funded chart-review support.
Corrections to this record
- 2026-09-04: Citation-hygiene fix: authors: 'Kasper D, May T, Crossland G, Lim HH.' → 'Kasper CA, May JM, Crossland NE, Lim HH'
Primary sources
Used as evidence for
This is an original summary from the Tinnitus Evidence verified database, checked against the primary source — not a reproduction of the publisher's abstract.